Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing

CardioVascular and Interventional Radiology

Volumn 37, Issue 3, 2014, Pages 631-638

  Karnabatidis, Dimitrios ^a   Spiliopoulos, Stavros ^a   Pastromas, Georgios ^a   Kitrou, Panagiotis ^a   Christeas, Nikolaos ^a   Katsanos, Konstantinos ^a   Siablis, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Aspirin; Clopidogrel; Dual nonresponsiveness; P2Y12 receptor assay; Peripheral arterial disease; Platelet responsiveness; Point of carte testing

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HOSPITAL INFORMATION SYSTEM; PERIPHERAL VASCULAR DISEASES; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; BLOOD PLATELETS; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; RISK FACTORS; TICLOPIDINE;

EID: 84901664820     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0710-3     Document Type: Article

References (43)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASCII). Eur J Vasc Endovasc Surg 33(Suppl 1):S1-S75 (Pubitemid 46068992)
2. Patrono C, Patrignani P (1984) Clinical pharmacology of acetylsalicylic acid as an antiplatelet agent. Atheroscler Rev 12:51
3. Antithrombotic Trialist's Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324(7330):141
4. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329-1339
5. Yusuf S, Zhao F, Metha SR, Chrolavicius S, Tognoni G, Fox KK (2001) The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
6. Savi P, Pereillo JM, Uzabiaga MF et al (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896
7. Mikhailidis DP, Jagroop IA (1998) Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 9:273-278 (Pubitemid 28473160)
8. Smith SJ, Allen J, Blair S, Bonow R, Brass L, Fonarow G et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363-2372 (Pubitemid 43947981)
9. Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51(19):1829-1843 (Pubitemid 351615246)
10. Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175
11. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505-1516 (Pubitemid 46517957)
12. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D (2013) Platelet REsponsiveness to CLOpidogrel treatment after Peripheral endovascular procedures - the PRECLOP Study: clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.03.036
13. Lev EI, Patel RT, Maresh KJ, Guthikonda S et al (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47:27-33 (Pubitemid 43005160)
14. Mueller MR, Salat A, Stangl P et al (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007 (Pubitemid 27417291)
15. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E (2002) Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13:493-497 (Pubitemid 35373664)
16. Born GV, Cross MJ (1963) The aggregation of blood platelets. J Physiol 168:178-195
17. Dichiara J, Bliden KP, Tantry US et al (2007) Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 18(6): 414-423 (Pubitemid 47347051)
18. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V (2006) Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28(5):315-322 (Pubitemid 44047198)
19. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, Fitzgerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809-1817
20. Nielsen HL, Kristensen SD, Thygesen SS et al (2008) Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 123(2):267-273
21. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E (2009) Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol 88(10):979-988
22. Madsen EH, Gehr NR, Johannesen NL, Schmidt EB, Kristensen SR (2011) Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets 22(7):537-546
23. Chen WH, Lee PY, Ng W, Tse HF, Lau CP (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43(6): 1122-1126 (Pubitemid 38353000)
24. Brar SS, ten Berg J, Marcucci R et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58(19):1945-1954
25. Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G (2011) Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 107(7):995-1000
26. Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51:1829-1843 (Pubitemid 351615246)
27. Maree AO, Fitzgerald DJ (2007) Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115:2196-2207 (Pubitemid 46659072)
28. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198 (Pubitemid 351212675)
29. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167: 1593-1599 (Pubitemid 47280339)
30. Gori AM, Marcucci R, Migliorini A et al (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52(9):734-739
31. Coma-Canella I, Velasc A (2007) Variability in individual responsiveness to aspirin: clinical implications and treatment. Cardiovasc Hematol Disord Drug Targets 7(4):274-287 (Pubitemid 350302902)
32. Coleman J, Wang JC, Simon JI (2004) Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point Care 3:77-82
33. Wang JC, Aucoin-Barry D, Manuelian D et al (2003) Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay - ASA. Am J Cardiol 92:1492-1494 (Pubitemid 37532584)
34. Paniccia R, Antonucci E, Gori AM et al (2007) Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 128(1):143-149 (Pubitemid 47121727)
35. Dahlen JR, Price MJ, Parise H, Gurbel PA (2013) Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 109(5):808-816
36. Pastromas G, Spiliopoulos S, Katsanos K et al (2013) Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Interv Radiol. doi:10.1007/s00270-013-0577-3
37. Price MJ, Nayak KR, Barker CM et al (2009) Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 103:1339-1343
38. Desai NR, Mega JL, Jiang S et al (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273-1278
39. Gurbel PA, Bliden KP, Logan DK et al (2013) The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX Study. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.03.037
40. van der Loo B, Braun J, Koppensteiner R (2011) On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty. Eur J Vasc Endovasc Surg 42:809-816
41. Linnemanna B, Schwonberg J, Toennes SW, Mani H, Lindhoff- Last E (2010) Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis 209:504-509
42. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDAPRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study. J Am Coll Cardiol 52:1128-1133
43. Rooke TW, Hirsch AT, Misra S et al (2013) Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61(14):1555-1570